Public Employees Retirement System of Ohio Makes New $1.10 Million Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Public Employees Retirement System of Ohio purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 7,376 shares of the biotechnology company’s stock, valued at approximately $1,101,000.

Several other large investors also recently made changes to their positions in the stock. Westfield Capital Management Co. LP raised its stake in shares of Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after buying an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after buying an additional 155,971 shares during the period. Finally, Groupama Asset Managment acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at $60,000.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ASND shares. Citigroup boosted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Oppenheimer decreased their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Wedbush reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Stock Up 1.5 %

NASDAQ ASND opened at $137.74 on Friday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The stock has a market cap of $8.35 billion, a P/E ratio of -17.05 and a beta of 0.67. The company’s 50-day simple moving average is $129.54 and its 200 day simple moving average is $132.81.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.